You searched for: ecog performance status (Engelska - Maltesiska)

ecog performance status, n (%)
stat ta’ prestazzjoni ecog, n (%)

weight, performance status
piż, status tal-prestazzjoni

baseline ecog performance status (ps) = 0
linja bażi ta’ ecog performance status (ps)= 0

baseline ecog performance status was 0 (31%) or 1 (69%).
l-istatus tal- prestazzjoni ecog fil-linja bażi kien 0 (31%) jew 1 (69%).

all patients had a baseline ecog performance status of 0 or 1.
il- pazjenti kollha kellhom stat ta’ eżekuzzjoni ta’ ecog ta’ 0 jew 1 fil-linja bażi.

baseline ecog performance status score was 0 (24%) or 1 (76%).
il- punteġġ tal-istatus tal-prestazzjoni ecog (eastern cooperative oncology group) fil-linja bażi kien 0 (24%) jew 1 (76%).

twenty-five percent of subjects had an ecog performance status ≥ 2.
Ħamsa u għoxrin fil-mija tal-individwi kellhom stat ta’ ħila ta’ ecog ta’ ≥2.

the majority of patients included had an ecog performance status of ≤ 1.
il-maġġoranza ta’ pazjenti inklużi kellhom stat ta’ prestazzjoni ecog ta’ ≤ 1.

only patients with ecog performance status 0 and 1 were enrolled in study go28141.
pazjenti bi stat ta’ ħila ta’ ecog ta’ 0 u 1 biss iddaħħlu fi studju go28141.

87% of patients enrolled had an ecog performance status score of 0-1.
87% tal-pazjenti rreġistrati kellhom punteġġ tal-istat ta’ ħila ecog ta’ 0-1.

# a total of 154 patients (ecog performance status 0 or 1) were randomized.
# total ta’ 154 pazjent (stat ta’ Ħila ta’ ecog ta’ 0 jew 1) kienu randomised.

clinical trials excluded patients with ecog performance status > 1 and mucosal melanoma.
provi kliniċi eskludew pazjenti bi stat ta’ prestazzjoni ecog > 1 u melanoma mukożali.

patients randomised to maintenance treatment were required to have an ecog performance status 0 or 1.
pazjenti li b’mod arbitrarju ġew magħżula biex jirċievu l-kura ta’ manteniment irid ikollhom stat ta’ għemil ecog ta’ 0 jew 1.

eastern cooperative oncology group (ecog) performance status (ps) ≥2 patients
pazjenti b’punteġġ ta’ eżekuzzjoni (ps - performance status) ta’ ≥2 tal-grupp ta’koperattiva tal- onkoloġija tal-lvant (ecog - eastern cooperative oncology group)

only patients with eastern cooperative oncology group (ecog) performance status 0 or 1 were eligible.
pazjenti bi stat ta’ Ħila (ps - performance status) tal-grupp tal-onkoloġija tal-kooperattiva tal-lvant (ecog - eastern cooperative oncology group) ta’ 0 jew 1 biss kienu eliġibbli.

the ecog performance status was comparable between both groups, as was the number and type of prior therapies.
l-istat tal-prestazzjoni ta’ l-ecog (eastern cooperative oncology group) kien komparabbli bejn iż-żewġ gruppi, kif kien ukoll in-numru u t-tip ta’ terapiji ta’ qabel.

male patients comprised 57% of study population and 70% of patients were baseline ecog 0 performance status.
57% tal-popolazzjoni tal- istudju kienu pazjenti rġiel u 70% tal-pazjenti kienu fi stat ta’ prestazzjoni ecog 0 fil-linja bażi.

p-value is derived from a log-rank test stratified by ecog performance status score (0-1 vs.
il-valur p jiġi kkalkulat permezz ta’ test log-rank stratifikat minn punteġġ ta’ status ta’ prestazzjoni ecog (0-1 vs.

limited data is available in the hetorgenous non-white population and patients with an ecog performance status of ps = 2.
dejta limitata hija disponibbli fil-popolazzjoni eteroġena mhux bajda u pazjenti bi status tal- prestazzjoni tal-ecog ta’ ps=2.

demographics were well balanced between the treatment arms (age, race, ecog performance status, and prior bevacizumab status).
id-demografija kienet ibbilanċjata tajjeb bejn il-gruppi ta’ kura (età, razza, ecog performance status, u l-istat ta’ qabel ta’ bevacizumab).